DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Opportunity For Licensing: Pharmaceutical Preparations Containing Cyclodextrin Derivatives
AGENCY: National Institutes of Health, Public Health Service, DHHS
ACTION: Notice
SUMMARY: The National Institutes of Health (NIH), Department of Health and Human Services, seeks licensee(s) for U.S. Patent 4,727,064, entitled "Pharmaceutical Preparations Containing Cyclodextrin Derivatives," which issued February 23, 1988. This invention describes a method of improvement of pharmaceutical preparations which comprises the addition of crystalline drugs with substantially low solubility to cyclodextrin compounds which are water soluble, have the ability to form inclusion complexes with the drugs in question, and are intrinsically amorphous and substantially decrease the tendency of the drug to crystallize.
This U.S. Patent had been exclusively licensed to Pharmatec Inc. and Cyclex Inc. (see Federal Register of September 10, 1987 - 52 FR 34268) by the National Technical Information Service (NTIS). The period of general exclusivity provided under the NTIS agreements has expired and the patent is now available for licensing. NTIS has transferred custody of this case to NIH and NIH has the right to grant nonexclusive or exclusive licenses to this patent in most fields of use. In particular, NIH can grant an exclusive license for the use of cyclodextrin technology in combination with "drug actives" that are approved for a particular use by the Food and Drug Administration (FDA) if the drug active itself or its FDA-approved use is covered by a U.S. patent.
NIH intends to grant the selected firm(s) royalty-bearing license(s) to practice the inventions embodied in U.S. Patent 4,727,064 in the U.S. for all or some of the available fields of use. The patent rights in these inventions have been assigned to the United States of America.
SUPPLEMENTAL INFORMATION: The NIH seeks licensee(s), who in accordance with requirements and regulations governing the licensing of government-owned inventions (37 CFR Part 404), have the most meritorious plan for the development of the cyclodextrin technology to a marketable status to meet the needs of the public and with the best terms for the NIH. The criteria that NIH will use to evaluate license applications will include, but not be limited to those set forth by 37 CFR 404.7(a)(1)(ii)-(iv).
ADDRESS: Requests for a copy of the patent, license application form, or other questions and comments concerning the licensing of this technology should be directed to: Carol C. Lavrich, Technology Licensing Specialist, Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852-3804; telephone: 301/496-7735 ext 287; fax: 301/402-0220.